A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
Public ClinicalTrials.gov record NCT03833180. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001)
Study identification
- NCT ID
- NCT03833180
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 91 participants
Conditions and interventions
Conditions
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Burkitt Lymphoma
- Chronic Lymphocytic Leukemia
- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma
- Lymphoplasmacytoid Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Richter Transformation Lymphoma
- T-cell Non-Hodgkin Lymphoma
- Waldenstrom Macroglobulinemia
Interventions
- Zilovertamab vedotin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 13, 2019
- Primary completion
- Dec 17, 2023
- Completion
- Dec 17, 2023
- Last update posted
- Jan 11, 2024
2019 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope ( Site 0010) | Duarte | California | 91010 | — |
| University of California - San Diego ( Site 0003) | La Jolla | California | 92093 | — |
| UCLA Hematology & Oncology ( Site 0007) | Los Angeles | California | 90095 | — |
| University of Nebraska Medical Center ( Site 0006) | Omaha | Nebraska | 68198-5331 | — |
| Northwell Health ( Site 0009) | New Hyde Park | New York | 11042 | — |
| Weill Cornell Medical College ( Site 0005) | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0014) | New York | New York | 10065 | — |
| University of Rochester ( Site 0008) | Rochester | New York | 14642 | — |
| Memorial Sloan-Kettering Cancer Center ( Site 0019) | Uniondale | New York | 11553 | — |
| Oregon Health & Science University ( Site 0004) | Portland | Oregon | 97239 | — |
| MD Anderson Cancer Center ( Site 0001) | Houston | Texas | 77030 | — |
| MD Anderson Cancer Center ( Site 0011) | Houston | Texas | 77030 | — |
| University of Virginia Cancer Center ( Site 0012) | Charlottesville | Virginia | 22908 | — |
| Swedish Medical Center ( Site 0002) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03833180, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 11, 2024 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03833180 live on ClinicalTrials.gov.